Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Total Liabilities (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Total Liabilities for 4 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 60.65% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 60.65% increase, with the full-year FY2024 number at $1.8 million, down 39.57% from a year prior.
  • Total Liabilities was $2.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $1.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $30.2 million in Q2 2023 to a low of $1.3 million in Q1 2024.
  • A 4-year average of $9.9 million and a median of $2.5 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: crashed 95.48% in 2024, then skyrocketed 60.65% in 2025.
  • 60 Degrees Pharmaceuticals' Total Liabilities stood at $25.4 million in 2022, then plummeted by 88.27% to $3.0 million in 2023, then crashed by 39.57% to $1.8 million in 2024, then rose by 29.82% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Total Liabilities are $2.3 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q1 2025).